Next Article in Journal
Patient and Provider Perspective of Smart Wearable Technology in Diabetic Foot Ulcer Prevention: A Systematic Review
Previous Article in Journal
Long-Term, Single-Centre Observation of Patients with Cardiac Implantable Electronic Devices
Case Report

Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

1
Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan
2
Department of Radiology, Taichung Veterans General Hospital, Taichung 40705, Taiwan
3
Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan
4
Integrated Care Center of Interstitial Lung Disease, Taichung Veterans General Hospital, Taichung 40705, Taiwan
*
Author to whom correspondence should be addressed.
Academic Editor: Emanuel Della-Torre
Medicina 2021, 57(12), 1358; https://doi.org/10.3390/medicina57121358
Received: 15 November 2021 / Revised: 9 December 2021 / Accepted: 10 December 2021 / Published: 13 December 2021
Anti-melanoma differentiation-associated protein 5 (MDA5)-positive rapidly progressive interstitial lung disease (RP-ILD) is associated with poor prognosis, and the most effective therapeutic intervention has not been established. Herein we report a case of a 45-year-old female patient who presented with myalgia, Gottron’s papules with ulceration, and dyspnea on exertion which became aggravated within weeks. Laboratory examination and electromyography confirmed myopathy changes, and a survey of myositis-specific antibodies was strongly positive for anti-MDA5 antibody. High-resolution chest tomography suggested organizing pneumonia with rapidly progressive changes within the first month after diagnosis of the disease. Anti-MDA5-associated dermatomyositis with RP-ILD was diagnosed. Following combination therapy with rituximab, tofacitinib and pirfenidone, clinical symptoms, including cutaneous manifestation, respiratory conditions and radiographic changes, showed significant and sustainable improvement. To our knowledge, this is the first reported case of anti-MDA5-associated dermatomyositis with RP-ILD successfully treated with the combination of rituximab, tofacitinib, and pirfenidone. View Full-Text
Keywords: MDA-5; RP-ILD; rituximab; tofacitinib; pirfenidone MDA-5; RP-ILD; rituximab; tofacitinib; pirfenidone
Show Figures

Figure 1

MDPI and ACS Style

Yen, T.-H.; Tseng, C.-W.; Wang, K.-L.; Fu, P.-K. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina 2021, 57, 1358. https://doi.org/10.3390/medicina57121358

AMA Style

Yen T-H, Tseng C-W, Wang K-L, Fu P-K. Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina. 2021; 57(12):1358. https://doi.org/10.3390/medicina57121358

Chicago/Turabian Style

Yen, Tsai-Hung, Chih-Wei Tseng, Kao-Lun Wang, and Pin-Kuei Fu. 2021. "Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report" Medicina 57, no. 12: 1358. https://doi.org/10.3390/medicina57121358

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop